flare-prediction
(2)
Progentec Diagnostics, Inc.
Progentec Diagnostics is an Oklahoma City company building blood-based biomarker tests and digital health tools for autoimmune diseases, starting with lupus. Its lead product, the aiSLE DX Flare Risk Index, uses an 11-biomarker algorithm to predict a lupus flare up to 12 weeks before it happens, giving rheumatologists a chance to intervene early. Spun out of research tied to the Oklahoma Medical Research Foundation, the company pairs lab science with patient-facing tools like the LupusCorner community to move autoimmune care from reactive to proactive.
Mohan Purushothaman
Mohan Purushothaman is the co-founder, chairman, and CEO of Progentec Diagnostics, an Oklahoma City company building blood tests and digital tools that aim to predict autoimmune disease flares before they happen. He came to diagnostics by an unusual route: a Johns Hopkins Ph.D. focused on pharmaceutical pricing, a Harvard research fellowship, five years inside Roche, and a pricing-software practice he built and sold to Alliance Life Sciences. In 2014 he turned that commercial instinct toward lupus, partnering with the Oklahoma Medical Research Foundation, and in 2020 raised a $5M Series A led by Plains Venture Partners to bring the aiSLE DX flare-prediction platform and the LupusCorner patient community to market.